U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07923708) titled 'Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Peri... Read More
U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07922551) titled 'Core Decompression Versus Core Decompression With Platelet-Rich Plasma Instillation for Trea... Read More
U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07922382) titled 'Integrated Attachment Theory' on Oct. 27. Brief Summary: This pilot randomized waitlist-con... Read More
U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07922590) titled 'A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation' on Nov. 02. Brief Summa... Read More
U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07922577) titled 'Bioactive Glass With or Without a Collagen Membrane for Periodontal Intrabony Defects' on No... Read More
U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07922135) titled 'Moderately Hypofractionated Versus Conventional Chemoradiotherapy With Consolidation Immunot... Read More
U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07923565) titled 'CANLINK: Evaluation of the Intralink Intradiscal Device for Low Back Pain Due to Degenerativ... Read More
New Delhi, Nov. 7 -- The National Green Tribunal has granted the Central Pollution Control Board (CPCB) eight weeks to place on record a further progress report on the development of uniform methodolo... Read More
Singapore, Nov. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to ... Read More
Singapore, Nov. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Part... Read More